Freenome uses a proprietary algorithm method to develop a multi-omics platform that reinvents disease management through systematized early detection and intervention. The company aims to empower everyone to prevent, detect, and treat their disease by creating next-generation blood tests that detect cancer in its earliest, most treatable stages. Freenome has raised over $1.1 billion from leading investors and has a culture of respect and cross-collaboration among its mission-driven employees, called "Freenomers."